Last reviewed · How we verify
NCT06260969
Endovascular Treatment of Acute Ischemic Stroke With Underlying Intracranial Artery Stenosis
trial testing balloon dilatation in Large Vessel Occlusion in 470 participants. Status unknown.
30 September 2025
Quick facts
| Lead sponsor | Tianjin Huanhu Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 470 |
| Start date | 1 September 2022 |
| Primary completion | 30 September 2025 |
| Estimated completion | 30 September 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- balloon dilatation
Conditions studied
- Large Vessel Occlusion — all drugs for Large Vessel Occlusion →
- Intracranial Artery Occlusion With Cerebral Infarction — all drugs for Intracranial Artery Occlusion With Cerebral Infarction →
- Endovascular Treatments — all drugs for Endovascular Treatments →
- Acute Ischemic Stroke — all drugs for Acute Ischemic Stroke →
Sponsor
Tianjin Huanhu Hospital
Who can join
18 and older, any sex, with Large Vessel Occlusion or Intracranial Artery Occlusion With Cerebral Infarction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study is a prospective multicentre registry study. Patients admitted to 10 stroke centres nationwide from September 2022 to September 2025 with acute ischaemic stroke due to large vessel occlusion considering underlying ICAS and treated with emergency endovascular thrombolysis were included for analysis. Patients who met the general inclusion criteria underwent thrombectomy and the necessary remedial treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06260969
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Large Vessel Occlusion
Currently open trials in the same condition.
- NCT07516522 — Intra-arterial Methylprednisolone After Endovascular Thrombectomy · Phase 2 · recruiting
- NCT07404852 — Non-invasive Vagus Nerve Stimulation to Reduce Inflammation and Brain Injury Blood Biomarkers Following an Acute Ischemi · NA · recruiting
- NCT07253181 — Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours · Phase 3 · recruiting
- NCT07174505 — Evaluation of the CONDA Stent Retriever in Acute Ischemic Stroke · NA · recruiting
- NCT06963489 — Cerebral Large Vessel Occlusion Stroke Multiomics Biosample Cohort · recruiting
Other Tianjin Huanhu Hospital trials
Trials by the same sponsor.
- NCT07386015 — Etiology-Phenotype-Outcome Pathway Study on Freezing of Gait (FOG) · recruiting
- NCT07365475 — Efficacy and Safety of Intra-Arterial Albumin as Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke · Phase 2 · not yet recruiting
- NCT07294391 — The Preliminary Efficacy and Safety of Intra-Arterial Albumin as Adjunct to Mechanical Thrombectomy in Acute Ischemic St · Phase 2 · not yet recruiting
- NCT07115511 — Combined Recanalization Therapy for Acute Large Vessel Occlusion Stroke · NA · recruiting
- NCT06621121 — A Real-world Study of Tenecteplase Versus Alteplase for Thrombolysis in Patients Within 4.5 H of Onset of Ischemic Strok · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06260969 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tianjin Huanhu Hospital
- Last refreshed: 15 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06260969.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing